| MeSH term | MeSH ID | Detail |
|---|---|---|
| Angioedema | D000799 | 6 associated lipids |
| Anus Diseases | D001004 | 3 associated lipids |
| Apraxias | D001072 | 1 associated lipids |
| Arm Injuries | D001134 | 1 associated lipids |
| Arterial Occlusive Diseases | D001157 | 12 associated lipids |
| Arteriosclerosis | D001161 | 86 associated lipids |
| Arthritis | D001168 | 41 associated lipids |
| Arthritis, Experimental | D001169 | 24 associated lipids |
| Arthritis, Infectious | D001170 | 8 associated lipids |
| Arthritis, Juvenile | D001171 | 8 associated lipids |
| Ascites | D001201 | 25 associated lipids |
| Ataxia | D001259 | 20 associated lipids |
| Ataxia Telangiectasia | D001260 | 6 associated lipids |
| Autoimmune Diseases | D001327 | 27 associated lipids |
| Autonomic Nervous System Diseases | D001342 | 4 associated lipids |
| Bacterial Infections | D001424 | 21 associated lipids |
| Balanitis | D001446 | 4 associated lipids |
| Beckwith-Wiedemann Syndrome | D001506 | 1 associated lipids |
| Behcet Syndrome | D001528 | 7 associated lipids |
| Biliary Fistula | D001658 | 13 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| McCune TR et al. | Effects of tacrolimus on hyperlipidemia after successful renal transplantation: a Southeastern Organ Procurement Foundation multicenter clinical study. | 1998 | Transplantation | pmid:9448150 |
| Busuttil RW and Lake JR | Role of tacrolimus in the evolution of liver transplantation. | 2004 | Transplantation | pmid:15201686 |
| First MR | Transplantation in the nineties. | 1992 | Transplantation | pmid:1370734 |
| Vincenti F | A decade of progress in kidney transplantation. | 2004 | Transplantation | pmid:15201687 |
| Bunnapradist S et al. | Graft survival following living-donor renal transplantation: a comparison of tacrolimus and cyclosporine microemulsion with mycophenolate mofetil and steroids. | 2003 | Transplantation | pmid:12865780 |
| Asberg A et al. | Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients. | 2006 | Transplantation | pmid:16861943 |
| Pfitzmann R et al. | Mycophenolatemofetil for immunosuppression after liver transplantation: a follow-up study of 191 patients. | 2003 | Transplantation | pmid:12865798 |
| Gonwa T et al. | Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years. | 2003 | Transplantation | pmid:12829910 |
| Chaftari AM et al. | Comparison of posaconazole versus weekly amphotericin B lipid complex for the prevention of invasive fungal infections in hematopoietic stem-cell transplantation. | 2012 | Transplantation | pmid:22814329 |
| Propper DJ et al. | FK506--its influence on anti-class 1 MHC alloantibody responses to blood transfusions. | 1990 | Transplantation | pmid:1696409 |
| Maruyama M et al. | Effect of FK506 treatment on allocytolytic T lymphocyte induction in vivo: differential effects of FK506 on L3T4+ and Ly2+ T cells. | 1990 | Transplantation | pmid:1696410 |
| Selzner N et al. | Conversion from cyclosporine to FK506 in adult liver transplant recipients: a combined North American and European experience. | 2001 | Transplantation | pmid:11579301 |
| Savoldo B et al. | Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients. | 2001 | Transplantation | pmid:11579304 |
| Sanchez-Campos S et al. | Cholestasis and alterations of glutathione metabolism induced by tacrolimus (FK506) in the rat. | 1998 | Transplantation | pmid:9679826 |
| Shao X et al. | Tacrolimus-associated ischemic optic neuropathy and posterior reversible encephalopathy syndrome after small bowel transplantation. | 2012 | Transplantation | pmid:23128973 |
| Iyengar AR et al. | Striking augmentation of hematopoietic cell chimerism in noncytoablated allogeneic bone marrow recipients by FLT3 ligand and tacrolimus. | 1997 | Transplantation | pmid:9158008 |
| Størset E et al. | Improved Tacrolimus Target Concentration Achievement Using Computerized Dosing in Renal Transplant Recipients--A Prospective, Randomized Study. | 2015 | Transplantation | pmid:25886918 |
| Platz KP et al. | Nephrotoxicity following orthotopic liver transplantation. A comparison between cyclosporine and FK506. | 1994 | Transplantation | pmid:7518975 |
| Takaya S et al. | Liver transplantation in positive cytotoxic crossmatch cases using FK506, high-dose steroids, and prostaglandin E1. | 1992 | Transplantation | pmid:1279851 |
| Wasik M et al. | Effect of FK506 versus cyclosporine on human natural and antibody-dependent cytotoxicity reactions in vitro. | 1991 | Transplantation | pmid:1702910 |
| Bronster DJ et al. | Tacrolimus-associated mutism after orthotopic liver transplantation. | 2000 | Transplantation | pmid:11014653 |
| Burroughs TE et al. | Increasing incidence of new-onset diabetes after transplant among pediatric renal transplant patients. | 2009 | Transplantation | pmid:19667939 |
| Mittal SK et al. | Increased interleukin-10 production without expansion of CD4+CD25+ T-regulatory cells in early stable renal transplant patients on calcineurin inhibitors. | 2009 | Transplantation | pmid:19667950 |
| Hoogtanders K et al. | Dried blood spot measurement of tacrolimus is promising for patient monitoring. | 2007 | Transplantation | pmid:17264824 |
| Sato T et al. | Diabetes mellitus after transplant: relationship to pretransplant glucose metabolism and tacrolimus or cyclosporine A-based therapy. | 2003 | Transplantation | pmid:14627910 |
| Hooper DK et al. | Risk of tacrolimus toxicity in CYP3A5 nonexpressors treated with intravenous nicardipine after kidney transplantation. | 2012 | Transplantation | pmid:22491658 |
| Ciancio G et al. | Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up. | 2008 | Transplantation | pmid:18622280 |
| Homma M et al. | Effects of lansoprazole and rabeprazole on tacrolimus blood concentration: case of a renal transplant recipient with CYP2C19 gene mutation. | 2002 | Transplantation | pmid:11821750 |
| Chakrabarti P et al. | Outcome after steroid withdrawal in pediatric renal transplant patients receiving tacrolimus-based immunosuppression. | 2000 | Transplantation | pmid:11003353 |
| Inoue T et al. | Lesser reduction in bone mineral density by the immunosuppressant, FK506, compared with cyclosporine in rats. | 2000 | Transplantation | pmid:11003356 |
| Iwata H et al. | Suppression of allograft responses by combining donor alloantigen-specific intravenous presensitization with suboptimal doses of FK506. | 1993 | Transplantation | pmid:7687396 |
| Shapiro R et al. | "Suboptimal" kidney donors: the experience with tacrolimus-based immunosuppression. | 1996 | Transplantation | pmid:8932264 |
| Nankivell BJ et al. | Calcineurin Inhibitor Nephrotoxicity Through the Lens of Longitudinal Histology: Comparison of Cyclosporine and Tacrolimus Eras. | 2016 | Transplantation | pmid:27306529 |
| Markus PM et al. | Effects of in vivo treatment with FK506 on natural killer cells in rats. | 1991 | Transplantation | pmid:1707562 |
| Neuhaus P et al. | Quadruple tacrolimus-based induction therapy including azathioprine and ALG does not significantly improve outcome after liver transplantation when compared with standard induction with tacrolimus and steroids: results of a prospective, randomized trial. | 2000 | Transplantation | pmid:10868638 |
| Ochiai T et al. | Studies of the effects of FK506 on renal allografting in the beagle dog. | 1987 | Transplantation | pmid:2447688 |
| De Ruvo N et al. | Preliminary results of a "prope" tolerogenic regimen with thymoglobulin pretreatment and hepatitis C virus recurrence in liver transplantation. | 2005 | Transplantation | pmid:16003226 |
| Mohamed MA et al. | TGF-beta expression in renal transplant biopsies: a comparative study between cyclosporin-A and tacrolimus. | 2000 | Transplantation | pmid:10755567 |
| Reich DJ et al. | Mycophenolate mofetil for renal dysfunction in liver transplant recipients on cyclosporine or tacrolimus: randomized, prospective, multicenter pilot study results. | 2005 | Transplantation | pmid:16003228 |
| Guasch A et al. | Assessment of efficacy and safety of FK778 in comparison with standard care in renal transplant recipients with untreated BK nephropathy. | 2010 | Transplantation | pmid:20811320 |
| Wennberg L et al. | Preapheresis immunosuppressive induction: necessary or harmful? | 2007 | Transplantation | pmid:18162987 |
| Ciancio G et al. | A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year. | 2004 | Transplantation | pmid:14742990 |
| Farley DE et al. | The effect of two new immunosuppressive agents, FK506 and didemnin B, in murine pregnancy. | 1991 | Transplantation | pmid:1713360 |
| Azzola A et al. | Everolimus and mycophenolate mofetil are potent inhibitors of fibroblast proliferation after lung transplantation. | 2004 | Transplantation | pmid:14742993 |
| Vathsala A et al. | The immunosuppressive antagonism of low doses of FK506 and cyclosporine. | 1991 | Transplantation | pmid:1713361 |
| Chavin KD et al. | Anti-CD2 monoclonal antibodies synergize with FK506 but not with cyclosporine or rapamycin to induce tolerance. | 1994 | Transplantation | pmid:7511258 |
| Hoerning A et al. | Pharmacodynamic monitoring of mammalian target of rapamycin inhibition by phosphoflow cytometric determination of p70S6 kinase activity. | 2015 | Transplantation | pmid:25099702 |
| Ricordi C et al. | In vivo effect of FK506 on human pancreatic islets. | 1991 | Transplantation | pmid:1716797 |
| Yilmaz MI et al. | Endothelial functions improve with decrease in asymmetric dimethylarginine (ADMA) levels after renal transplantation. | 2005 | Transplantation | pmid:16378057 |
| Zhang W et al. | Isoglycyrrhizinate Magnesium Enhances Hepatoprotective Effect of FK506 on Ischemia-Reperfusion Injury Through HMGB1 Inhibition in a Rat Model of Liver Transplantation. | 2017 | Transplantation | pmid:28885495 |